Abstract
Lactoferricin (LFcin) was initially identified as an antimicrobial peptide derived by pepsin digestion of lactoferrin (LF), a multifunctional innate-defense protein in milk. Various synthetic analogs of LFcin have also been reported. LFcin inhibits a diverse range of microorganisms such as gram-negative bacteria, gram-positive bacteria, yeast, filamentous fungi, and parasitic protozoa, including some antibiotic-resistant pathogens. LFcin kills target organisms by membrane perturbation and acts synergistically with some antimicrobial agents. LFcin exhibits numerous biological activities in common with those of LF. Whereas LFcin suppresses the activation of innate immunity by microbial components such as lipopolysaccharide (LPS) and CpG DNA, the peptide itself activates immunity. Administration of LFcin analogs has been shown to protect the host via direct antimicrobial activity and immunostimulatory effects in several infection models of mice. Here we present a comprehensive review of investigations of LFcin and related peptides.
Keywords: milk, lactoferrin, lactoferricin, lfcin, antimicrobial, peptide, immunomodulation, multifunctional
Current Pharmaceutical Design
Title: Lactoferricin Derived From Milk Protein Lactoferrin
Volume: 9 Issue: 16
Author(s): H. Wakabayashi, M. Takase and M. Tomita
Affiliation:
Keywords: milk, lactoferrin, lactoferricin, lfcin, antimicrobial, peptide, immunomodulation, multifunctional
Abstract: Lactoferricin (LFcin) was initially identified as an antimicrobial peptide derived by pepsin digestion of lactoferrin (LF), a multifunctional innate-defense protein in milk. Various synthetic analogs of LFcin have also been reported. LFcin inhibits a diverse range of microorganisms such as gram-negative bacteria, gram-positive bacteria, yeast, filamentous fungi, and parasitic protozoa, including some antibiotic-resistant pathogens. LFcin kills target organisms by membrane perturbation and acts synergistically with some antimicrobial agents. LFcin exhibits numerous biological activities in common with those of LF. Whereas LFcin suppresses the activation of innate immunity by microbial components such as lipopolysaccharide (LPS) and CpG DNA, the peptide itself activates immunity. Administration of LFcin analogs has been shown to protect the host via direct antimicrobial activity and immunostimulatory effects in several infection models of mice. Here we present a comprehensive review of investigations of LFcin and related peptides.
Export Options
About this article
Cite this article as:
Wakabayashi H., Takase M. and Tomita M., Lactoferricin Derived From Milk Protein Lactoferrin, Current Pharmaceutical Design 2003; 9 (16) . https://dx.doi.org/10.2174/1381612033454829
DOI https://dx.doi.org/10.2174/1381612033454829 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers
Current Drug Delivery Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Alcoholic Liver Disease and Hepatitis C Chronic Infection
Reviews on Recent Clinical Trials Pleiotropic Functions of Rho GTPase Signaling: A Trojan Horse or Achilles Heel for Breast Cancer Treatment?
Current Drug Targets Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Synthesis and Characterization of 1-carboxyphenothiazine Derivatives Bearing Nitrogen Mustard as Promising Class of Antitubercular Agents
Letters in Drug Design & Discovery Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Mesenchymal Stromal Cell Secretome: Immunomodulation, Tissue Repair and Effects on Neurodegenerative Conditions
Current Stem Cell Research & Therapy Molecule of the Month
Current Topics in Medicinal Chemistry The Integrative Network of Gene Expression, MicroRNA, Methylation and Copy Number Variation in Colon and Rectal Cancer
Current Bioinformatics Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia
Current Drug Metabolism Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Polynucleotide Kinase as a Potential Target for Enhancing Cytotoxicity by Ionizing Radiation and Topoisomerase I Inhibitors
Anti-Cancer Agents in Medicinal Chemistry An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
Current Computer-Aided Drug Design